eLucid mHealth Limited

Life Sciences
Medical Technology
Aim of funding: 
HMRC Advance Assurance received: 

eLucid mHealth Limited


eLucid mHealth is a medication technology company creating proprietary, patented automatic adherence/compliance monitoring tools as part of an integrated healthcare system.

eLucid mHealth’s solutions and devices have been specifically designed with patient feedback; they are non-invasive and simple to use. The company’s priority objective is to improve patient adherence across all different types of medication. To achieve this goal the company proposes to develop a strong, diverse portfolio of solutions.

All of the company’s products are moving towards CE accreditation within the next 12 months.           


eLucid mHealth's primary market is pharmaceutical R&D, commonly known as the clinical trial supply (CTS) industry, with ICON PLC (January 2015) suggesting that this market will be worth US$148 billion per year by 2020.

New molecules and drug compounds are tested on patients to determine the level of efficacy and performance in treating diseases. On average, CTS trials are extremely costly and time consuming –e.g. a phase 3 cancer trial can cost up to US$41 million. The efficacy of new drugs in clinical trials is dependent on patient compliance including medication adherence, which accounts up to one third of the costs of the total trial costs.

It is the intention of the eLucid mHealth team to produce through continued R&D activities ‘gold standard’ monitoring tools and data informatics that deliver a far improved ROI following sizeable drug trials for large pharma.

Information on this webpage relates to and is provided by Deepbridge Advisers Limited.

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Deepbridge Capital LLP, Deepbridge Advisers Limited and Enterprise Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.